Summary
Solar‐driven converting CO2 to value‐added chemicals can not only address the ever‐growing energy crisis, but also simultaneously mitigate CO2 emission. Although much progress has been made in the last decade, it still remains great challenge to achieve the efficient reduction of CO2 with desirable productivity and high product selectivity because CO2 is a thermodynamically stable and inert molecule with large bond energy. Design and synthesis of efficient catalyst play a pivotal role in promoting the activity and selectivity of photocatalytic CO2 reduction. Apart from the active sites engineering, manipulation of the charge separation and light harvesting efficiency or prolonging the lifetime of photogenerated carriers also greatly matters. Consequently, this review summarizes recent advances in photocatalyst design for CO2 conversion from two major aspects, namely active sites engineering and carriers lifespan prolonging. Firstly, we sort out the fundamental principles and merits of artificial photosynthesis in order to provide readers with a current snapshot of this rapidly developed field. Subsequently, various catalyst engineering strategies, including doping, alloying, Z‐scheme structure construction, are discussed in detail. Finally, some challenging issues as well as insights into the future development of artificial photosynthesis are presented.
In the past few years, binary colloidal crystals (BCCs) composed of both large and small particles have attracted considerable attention from the scientific community as an exciting alternative to single colloidal crystals (SCCs). In particular, more complex structures with diverse nanotopographies and desirable optical properties of BCCs can be obtained by various colloidal assembly methods, as compared to SCCs. Furthermore, high accuracy in crystal growth with controllable stoichiometries allows for a great deal of promising applications in the fields of both interfacial and material sciences. The visible-light diffraction property of BCCs is more superior than that of SCCs, which makes them have more promising applications in the fabrication of photonic crystals with full band gaps. On the other hand, their spherical shapes and ease of removal property make them ideal templates for ordered porous material fabrication. Hence, this perspective outlined recent advances in assembly approaches of BCCs, with an emphasis on their promising applications for advanced photonics and multifunctional porous material fabrication. Eventually, some challenging yet important issues and some future perspectives are further discussed.
Drug-induced gingival overgrowth (DIGO) is recognized as a side effect of nifedipine (NIF); however, the underlying molecular mechanisms remain unknown. In this study, we found that overexpressed miR-4651 inhibits cell proliferation and induces G0/G1phase arrest in gingival mesenchymal stem cells (GMSCs) with or without NIF treatment. Furthermore, sequential window acquisition of all theoretical mass spectra (SWATH-MS) analysis, bioinformatics analysis, and dual-luciferase report assay results confirmed that high-mobility group AT-hook 2 (HMGA2) is the downstream target gene of miR-4651. Overexpression of HMGA2 enhanced GMSC proliferation and accelerated the cell cycle with or without NIF treatment. The present study demonstrates that miR-4651 inhibits the proliferation of GMSCs and arrests the cell cycle at the G0/G1 phase by upregulating cyclin D and CDK2 while downregulating cyclin E through inhibition of HMGA2 under NIF stimulation. These findings reveal a novel mechanism regulating DIGO progression and suggest the potential of miR-4651 and HMGA2 as therapeutic targets.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.